India IP Policy Misrepresented By US Trade Representative, Indian Pharma Says
An Indian pharmaceutical industry group has challenged the United States Trade Representative’s assessment of India’s intellectual property protection regime and suggested that India received more severe treatment than other countries solely on the basis of treatment of patented pharmaceuticals that it says is allowed under international rules.
